Amyloid-β immunisation for Alzheimer's disease

The Lancet Neurology

Volumn 7, Issue 9, 2008, Pages 805-811

  Wisniewski, Thomas ^a   Konietzko, Uwe ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACC 001; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN VACCINE; BAPINEUZUMAB; CAD 106; DIMER; IMMUNOGLOBULIN; LY 2062430; OLIGOMER; PEPTIDE VACCINE; PF 04360365; PROTEIN PRECURSOR; QS 21; R 1450; R1450; UNCLASSIFIED DRUG; V 950; V950; VACCINE;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AUTOIMMUNITY; CLINICAL TRIAL; FAMILIAL AMYLOIDOSIS; GENE MUTATION; HUMAN; IMMUNIZATION; IMMUNOMODULATION; IMMUNOTHERAPY; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; PASSIVE IMMUNIZATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; REVIEW;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY, ACTIVE; MICE; PROTEIN CONFORMATION; SENILE PLAQUES;

EID: 48949085739     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70170-4     Document Type: Review

References (85)

1. Winklhofer K.F., Tatzelt J., and Haass C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J 27 (2008) 336-349
2. Blennow K., De Leon M.J., and Zetterberg H. Alzheimer's disease. Lancet 368 (2006) 387-403
3. Zheng H., and Koo E.H. The amyloid precursor protein: beyond amyloid. Mol Neurodegener 1 (2006) 5
4. Knobloch M., Farinelli M., Konietzko U., Nitsch R.M., and Mansuy I.M. Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J Neurosci 27 (2007) 7648-7653
5. Wisniewski T., Castaño E.M., Golabek A.A., Vogel T., and Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 145 (1994) 1030-1035
6. Ma J., Yee A., Brewer Jr. H.B., Das S., and Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372 (1994) 92-94
7. Johnson L.V., Leitner W.P., Rivest A.J., Staples M.K., Radeke M.J., and Anderson D.H. The Alzheimer's A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA 99 (2002) 11830-11835
8. Boyett K.W., DiCarlo G., Jantzen P.T., et al. Increased fibrillar beta-amyloid in response to human C1q injections into hippocampus and cortex of APP+PS1 transgenic mice. Neurochem Res 28 (2003) 83-93
9. Wisniewski T., Lalowski M., Golabek A.A., Vogel T., and Frangione B. Is Alzheimer's disease an apolipoprotein E amyloidosis?. Lancet 345 (1995) 956-958
10. Wisniewski H.M., Sadowski M., Jakubowska-Sadowska K., Tarnawski M., and Wegiel J. Diffuse, lake-like amyloid-beta deposits in the parvopyramidal layer of the presubiculum in Alzheimer disease. J Neuropathol Exp Neurol 57 (1998) 674-683
11. Shibata M., Yamada S., Kumar S., et al. Clearance of Alzheimer's amyloid-β 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106 (2000) 1489-1499
12. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
13. Hardy J. A hundred years of Alzheimer's disease research. Neuron 52 (2006) 3-13
14. Lemere C.A., Blusztajn J.K., Yamaguchi H., Wisniewski T., Saido T.C., and Selkoe D.J. Sequence of deposition of heterogeneous amyloid β-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 3 (1996) 16-32
15. Gotz J., Chen F., van D.J., and Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293 (2001) 1491-1495
16. Oddo S., Caccamo A., Shepherd J.D., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39 (2003) 409-421
17. King M.E., Kan H.M., Baas P.W., Erisir A., Glabe C.G., and Bloom G.S. Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol 175 (2006) 541-546
18. Schenk D., Barbour R., Dunn W., et al. Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mice. Nature 400 (1999) 173-177
19. Sigurdsson E.M., Scholtzova H., Mehta P., Frangione B., and Wisniewski T. Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am J Pathol 159 (2001) 439-447
20. Morgan D., Diamond D.M., Gottschall P.E., et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2001) 982-985
21. Janus C., Pearson J., McLaurin J., et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
22. Oddo S., Caccamo A., Tran L., et al. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease: a link between Abeta and tau pathology. J Biol Chem 281 (2006) 1599-1604
23. Blurton-Jones M., and LaFerla F.M. Pathways by which Abeta facilitates tau pathology. Curr Alzheimer Res 3 (2006) 437-448
24. McKee A.C., Carreras I., Hossain L., et al. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 1207 (2008) 225-236
25. Castellani R.J., Lee H.G., Zhu X., Perry G., and Smith M.A. Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol 67 (2008) 523-531
26. Crystal H.A., Dickson D.W., Sliwinski M.J., et al. Pathological markers associated with normal aging and dementia in the elderly. Ann Neurol 34 (1993) 566-573
27. Knopman D.S., Parisi J.E., Salviati A., et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 62 (2003) 1087-1095
28. Naslund J., Haroutunian V., Mohs R., et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283 (2000) 1571-1577
29. Meyer-Luehmann M., Coomaraswamy J., Bolmont T., et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313 (2006) 1781-1784
30. Shankar G.M., Li S., Mehta T.H., et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 10.1038/nm1782 published online June 22.
31. Shioi J., Georgakopoulos A., Mehta P., et al. FAD mutants unable to increase neurotoxic Abeta 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta. J Neurochem 101 (2007) 674-681
32. Sigurdsson E.M., Knudsen E.L., Asuni A., et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-β derivatives. J Neurosci 24 (2004) 6277-6282
33. Asuni A., Boutajangout A., Scholtzova H., et al. Aβ derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhemorrhages in Alzheimer's model mice. Eur J Neurosci 24 (2006) 2530-2542
34. Bard F., Cannon C., Barbour R., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of alzheimer disease. Nat Med 6 (2000) 916-919
35. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98 (2001) 8850-8855
36. Golde T.E. Disease modifying therapy for AD?. J Neurochem 99 (2006) 689-707
37. Kennedy G.J., Golde T.E., Tariot P.N., and Cummings J.L. Amyloid-Based interventions in Alzheimer's disease. CNS Spectr 12 12 suppl 1 (2007) 1-14
38. Bolmont T., Clavaguera F., Meyer-Luehmann M., et al. Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol 171 (2007) 2012-2020
39. Bacskai B.J., Kajdasz S.T., Christie R.H., et al. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7 (2001) 369-372
40. Solomon B., Koppel R., Hanan E., and Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc Natl Acad Sci USA 93 (1996) 452-455
41. Solomon B., Koppel R., Frankel D., and Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 94 (1997) 4109-4112
42. Frenkel D., Solomon B., and Benhar I. Modulation of Alzheimer's beta-amyloid neurotoxicity by site-directed single-chain antibody. J Neuroimmunol 106 (2000) 23-31
43. Das P., Howard V., Loosbrock N., Dickson D., Murphy M.P., and Golde T.E. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci 23 (2003) 8532-8538
44. Bacskai B.J., Kajdasz S.T., McLellan M.E., et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 22 (2002) 7873-7878
45. Wilcock D.M., Rojiani A., Rosenthal A., et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24 (2004) 6144-6151
46. Sigurdsson E.M., Wisniewski T., and Frangione B. A safer vaccine for Alzheimer's disease?. Neurobiol Aging 23 (2002) 1001-1008
47. Brody D.L., and Holtzman D.M. Active and passive immunotherapy for neurodegenerative diseass. Annu Rev Neurosci 31 (2008) 175-193
48. Wisniewski T., and Frangione B. Immunological and anti-chaperone therapeutic approaches for Alzheimer's disease. Brain Pathol 15 (2005) 72-77
49. Bayer A.J., Bullock R., Jones R.W., et al. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology 64 (2005) 94-101
50. Pride M., Seubert P., Grundman M., Hagen M., Eldridge J., and Black R.S. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis 5 (2008) 194-196
51. Wisniewski T. Practice point commentary on "Clinical effects of Aβ immunization (AN1792) in patients with AD in an interupted trial". Nat Clin Prac Neurol 1 (2005) 84-85
52. Boche D., and Nicoll J.A. The role of the immune system in clearance of Abeta from the brain. Brain Pathol 18 (2008) 267-278
53. Bombois S., Maurage C.A., Gompel M., et al. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch Neurol 64 (2007) 583-587
54. Ferrer I., Boada R.M., Guerra M.S., Rey M.J., and Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14 (2004) 11-20
55. Masliah E., Hansen L., Adame A., et al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64 (2005) 129-131
56. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9 (2005) 448-452
57. Nicoll J.A., Barton E., Boche D., et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 65 (2006) 1040-1048
58. Sadowski M., and Wisniewski T. Disease modifying approaches for Alzheimer's pathology. Current Pharmaceutic Design 13 (2007) 1943-1954
59. Hock C., Konietzko U., Straffer J.R., et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 (2003) 547-554
60. Hock C., Konietzko U., Paspassotiropoulos A., et al. Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nat Med 8 (2002) 1270-1276
61. Gilman S., Koller M., Black R.S., et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interupted trial. Neurology 64 (2005) 1553-1562
62. 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372 (2008) 216-223
63. Head E., Pop V., Vasilevko V., et al. A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J Neurosci 28 (2008) 3555-3566
64. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., and LaFerla F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43 (2004) 321-332
65. Relkin N.R., Szabo P., Adamiak B., et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging (2008) 10.1016/j.neurobiolaging.2007.12.021 published online Feb 20.
66. Robinson S.R., Bishop G.M., Lee H.G., and Munch G. Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol Aging 25 (2004) 609-615
67. Wyeth. Elan and Wyeth announce encouraging top-line results from phase 2 clinical trial of bapineuzumab for Alzheimer's disease. http://wyeth.com/news?nav=display&navTo=/wyeth_html/home/news/pressr eleases/2008/1213683456273.html (accessed July 23, 2008).
68. Solomon B. Antibody-mediated immunotherapy for Alzheimer's disease. Curr Opin Investig Drugs 8 (2007) 519-524
69. Jellinger K.A. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 109 (2002) 813-836
70. Zhang-Nunes S.X., Maat-Schieman M.L., Van Duinen S.G., Roos R.A., Frosch M.P., and Greenberg S.M. The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol 16 (2006) 30-39
71. Pfeifer M., Boncristiano S., Bondolfi L., et al. Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 298 (2002) 1379
72. Wilcock D.M., Rojiani A., Rosenthal A., et al. Passive immunization against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1 (2004) 24
73. Racke M.M., Boone L.I., Hepburn D.L., et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhages in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyoid beta. J Neurosci 25 (2005) 629-636
74. Wilcock D.M., Jantzen P.T., Li Q., Morgan D., and Gordon M.N. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 144 (2007) 950-960
75. Singh H., and Raghava G.P. ProPred: prediction of HLA-DR binding sites. Bioinformatics 17 (2001) 1236-1237
76. Singh H., and Raghava G.P. ProPred1: prediction of promiscuous MHC class-I binding sites. Bioinformatics 19 (2003) 1009-1014
77. Lemere C.A., Maron R., Selkoe D.J., and Weiner H.L. Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol 20 (2001) 705-711
78. Zhang J., Wu X., Qin C., et al. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol Dis 14 (2003) 365-379
79. Weiner H.L., Lemere C.A., Maron R., et al. Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48 (2000) 567-579
80. Goni F., Chabalgoity J.A., Prelli F., et al. High titers of mucosal and systemic anti-PrP antibodies abrogates oral prion infection in mucosal vaccinated mice. Neuroscience 153 (2008) 679-686
81. Movsesyan N., Ghochikyan A., Mkrtichyan M., et al. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS ONE 3 (2008) e2124
82. Crack P.J., and Bray P.J. Toll-like receptors in the brain and their potential roles in neuropathology. Immunol Cell Biol 85 (2007) 476-480
83. Spinner D.S., Kascsak R.B., LaFauci G., et al. CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils. J Leukoc Biol 14 (2007) 36-43
84. Rosset M.B., Ballerini C., Gregoire S., Metharom P., Carnaud C., and Aucouturier P. Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice. J Immunol 172 (2004) 5168-5174
85. Town T., Laouar Y., Pittenger C., et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 14 (2008) 681-687